Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
ID: ALA4209781
Max Phase: Preclinical
Molecular Formula: C33H33N5O4
Molecular Weight: 563.66
Molecule Type: Small molecule
Associated Items:
ID: ALA4209781
Max Phase: Preclinical
Molecular Formula: C33H33N5O4
Molecular Weight: 563.66
Molecule Type: Small molecule
Associated Items:
Canonical SMILES: Nc1ncnc2c1c(-c1ccc(Oc3ccccc3)cc1)cn2[C@H]1CC[C@H](N[C@@H](Cc2ccc(O)cc2)C(=O)O)CC1
Standard InChI: InChI=1S/C33H33N5O4/c34-31-30-28(22-8-16-27(17-9-22)42-26-4-2-1-3-5-26)19-38(32(30)36-20-35-31)24-12-10-23(11-13-24)37-29(33(40)41)18-21-6-14-25(39)15-7-21/h1-9,14-17,19-20,23-24,29,37,39H,10-13,18H2,(H,40,41)(H2,34,35,36)/t23-,24-,29-/m0/s1
Standard InChI Key: IVZNWJUHDBLKKT-MOMDTQCHSA-N
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
Molecule Type: Small molecule | Topical: No | First In Class: No | Black Box: No |
Chirality: No | Availability: No | Prodrug: No |
MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
---|
Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
---|
Molecular Weight: 563.66 | Molecular Weight (Monoisotopic): 563.2533 | AlogP: 5.95 | #Rotatable Bonds: 9 |
Polar Surface Area: 135.52 | Molecular Species: ZWITTERION | HBA: 8 | HBD: 4 |
#RO5 Violations: 2 | HBA (Lipinski): 9 | HBD (Lipinski): 5 | #RO5 Violations (Lipinski): 2 |
CX Acidic pKa: 0.91 | CX Basic pKa: 10.95 | CX LogP: 3.25 | CX LogD: 3.12 |
Aromatic Rings: 5 | Heavy Atoms: 42 | QED Weighted: 0.17 | Np Likeness Score: -0.22 |
1. Koda Y, Kikuzato K, Mikuni J, Tanaka A, Yuki H, Honma T, Tomabechi Y, Kukimoto-Niino M, Shirouzu M, Shirai F, Koyama H.. (2017) Identification of pyrrolo[2,3-d]pyrimidines as potent HCK and FLT3-ITD dual inhibitors., 27 (22): [PMID:29037944] [10.1016/j.bmcl.2017.10.012] |
Source(1):